Abstract

A 64-year-old woman with chronic lymphocytic leukemia presented with a 2-week history of burning and painful nodules on her legs, abdomen, and arms. Her eruption started 4 days after she began taking the clinical trial drug navitoclax, a targeted smallmolecule antagonist of the antiapoptotic lymphocytic protein Bcl-2. Otherwise, she felt well and denied recent travel. Physical examination revealed numerous tender, erythematous to ulceronecrotic, 1to 3-cm nodules onher arms, abdomen, and thighs (Figure 1). The early lesions were slightly erythematous indurated plaques. The later lesions were necrotic and purulent nodules. Six biopsy specimens were obtained from the necrotic lesions, 3 for histologic examination and 3 for culture. Histologic examination showed suppurative inflammation with tissue necrosis, with no organisms identified on special stains. All tissue cultures were negative for organisms. Based on this information, a 3-week regimen of empirical coverage for atypical mycobacteria with doxycycline hydrochloride, ciprofloxacin, and clarithromycin was initiated. The therapy was discontinued when the patient showed no improvement. Subsequently, oral prednisone therapy (60 mg/d) for a presumed neutrophilic dermatosis was initiated; however, it was discontinued 3 days later because of clinical deterioration. Another biopsy was performed on a new early lesion on the right side of the patient’s back (Figure 2 and Figure 3). What is your diagnosis?

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.